Last reviewed · How we verify
NCT06596603: CAN-REST
Contrast-Associated Nephropathy Risk Evaluation in Acute Ischemic Stroke After Endovascular Thrombectomy
trial in Contrast-Associated Acute Kidney Injury in 8,000 participants. Completed in 1 July 2025.
31 December 2024
Quick facts
| Lead sponsor | Niguarda Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 8,000 |
| Start date | 1 March 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 1 July 2025 |
| Sites | 1 location across Italy |
Conditions studied
- Contrast-Associated Acute Kidney Injury — all drugs for Contrast-Associated Acute Kidney Injury →
Sponsor
Niguarda Hospital
Who can join
18 and older, any sex, with Contrast-Associated Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The CAN-REST study is a multicenter, observational, and retrospective study aimed at evaluating the incidence and risk factors of contrast-associated acute kidney injury (CA-AKI) in patients with acute ischemic stroke (AIS) who undergo endovascular thrombectomy (EVT). This study is conducted across multiple centers in Italy, Europe, the USA, and Canada, and includes data from AIS patients treated with EVT in 2023. The primary objectives are to assess the incidence of CA-AKI in this population and identify associated risk factors. Secondary objectives include evaluating the impact of CA-AKI on clinical outcomes, such as the length of hospital stay, functional recovery, and 90-day mortality, as well as developing risk stratification tools to predict CA-AKI. By analyzing a large cohort of patients, CAN-REST aims to provide critical insights into the renal complications associated with EVT and establish predictive models that can guide clinical decision-making and improve patient outcomes.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
11th European Stroke Organisation Conference Abstracts - 21-23 May 2025, Helsinki, Finland: Late Breaking Abstracts.
· 2025 · cited 1× · PMID 40726473 · DOI 10.1177/23969873251345751 -
Contrast-Associated Acute Kidney Injury After Thrombectomy for Ischemic Stroke: Prognostic Impact and CAN-REST Predictive Score.
Schwarz G, Cascio Rizzo A, Ambler G, Wrona P, et al · · 2026 · PMID 41712884 · DOI 10.1212/wnl.0000000000214655
Verify or expand the search:
- PubMed search for NCT06596603
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Contrast-Associated Acute Kidney Injury
Currently open trials in the same condition.
- NCT07459413 — Oral vs. Intravenous Hydration to Prevent Contrast-Associated Acute Kidney Injury in the ED · NA · recruiting
Other Niguarda Hospital trials
Trials by the same sponsor.
- NCT05105399 — Evaluation of Serratus Plane Block on the Respiratory Pattern in Patients With Multiple Rib Fractures · NA · not yet recruiting
- NCT07153224 — The MICROSCOPE Project · not yet recruiting
- NCT04763993 — Reflux Disease After Gastric Bypass Versus Sleeve Gastrectomy in Morbid Obese Patients: an Italian Study · NA · not yet recruiting
- NCT07432347 — Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches · recruiting
- NCT07234409 — Clinical Trial Addressing the Best Surgical Approach for Partial Nephrectomy With Single Port Robotic System in the Mana · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06596603 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Niguarda Hospital
- Last refreshed: 30 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06596603.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing